ESC 2026 marked a turning point — GLP-1s earn their first formal heart failure guideline recommendation and become a cardiometabolic platform.
Stylianos Sarrigiannidis
Advertisement
Stylianos Sarrigiannidis is a Senior Business Analyst with Lifescience Dynamics, exercising his expertise in cutting-edge developments across autoimmune diseases like SLE and cell therapies such as CAR-Ts. He endeavors to provide strategic insights to advance innovation and study patient outcomes in these transformative fields. Before joining Lifescience Dynamics, Sarrigiannidis earned a PhD in Biomedical Engineering at the University of Glasgow, where he focused on drug delivery mechanisms, tissue regeneration, and biomaterials.
Articles by Stylianos Sarrigiannidis
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Caribou Biosciences Discontinues Development for Vispa-cel & CB-011 CAR-T Cell Therapy Programs
2
FDA Approves Tukysa Plus Trastuzumab and Pertuzumab as First-Line Maintenance Treatment for HER2-Positive Metastatic Breast Cancer
3
Pharmaceutical Executive Daily: FDA Approves Tukysa Plus Trastuzumab and Pertuzumab
4
The Unmet Needs That Will Define the Next Generation of GLP 1s: Q&A with Dr. Bo Liang
5